Stock comparison
ANI Pharmaceuticals
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ANIP
ANI Pharmaceuticals
Market cap
$1.88B
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ANIP | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 53C | 72B | RMD |
| Benjamin Graham | 59D | 75B | RMD |
| Philip Fisher | 58C | 75B | RMD |
| Peter Lynch | 71C | 58C | ANIP |
| Joel Greenblatt | 44D | 47D | RMD |
| Charlie Munger | 47D | 69B | RMD |
| Terry Smith | 50D | 73B | RMD |
Side-by-side metrics
| Metric | ANIP | RMD |
|---|---|---|
| Market cap | $1.88B | $30.18B |
| P/E (TTM) | 18.5x | 19.6x |
| EV/EBIT | 22.4x | 17.1x |
| ROIC (TTM) | 8.17% | 19.63% |
| Gross margin | 65.94% | 61.69% |
| Net margin | 9.71% | 27.44% |
| Revenue CAGR 5y | 42.18% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.6x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ANIP leads on
- Revenue CAGR 5y42.18%vs 12.64%+70%
- Gross margin65.94%vs 61.69%+6%
- P/E (TTM)18.5xvs 19.6x+6%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.88B+94%
- Debt / Equity0.1xvs 0.6x+78%
- Net margin27.44%vs 9.71%+65%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.